Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer J. 2011 Sep;17(5):302–308. doi: 10.1097/PPO.0b013e318233e6b4

Table 1.

Vaccines trials at an advanced stage in non-small cell lung cancer

Vaccine Patient Population Clinical Trial
Allogeneic

Tumor Cell

Vaccines 		Belagenpumatucel-L (Lucanix®) IIIA/IIIB/IV STOP trial – Phase III. Maintenance therapy for patients who have responded to or have stable disease following first-line, platinum-based combination chemotherapy (NCT00676507)
Protein

Specific

Vaccines 		MAGE-A3 IB/II or IIIA MAGRIT trial – Phase III. Adjuvant therapy in patients with resectable MAGE-A3 positive NSCLC (NCT00480025)
EGF IIIB/IV A Phase II/III trial of recombinant human EGF-rP64K/Montanide ISA 51 vaccine administered to patients after conventional first line chemotherapy (NCT00516685)
MUC-1 Unresectable stage IIIA/IIB START TRIAL. Phase III trial of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in patients with stable disease or response following chemoradiation (NCT00409188)